trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['tnbc']
 for tnbc- immunotherapy still first if pd-l1 pos. if pd-l1 neg, still need at least one prior chemo. in this study, patients had to receive one or two previous lines of chemotherapy before t-dxd. #asco22
Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ??